Pioneering the next frontier of extracellular protein degradation
We are harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD)
Led by a highly experienced team of pharma and biotech industry leaders and backed by a syndicate of leading European investors - Gilde Healthcare Partners, Inkef Capital, Novo Seeds and MP Healthcare Venture Management – we are extending the potential of protein degradation to target extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors, and has the potential to revolutionise the field of TPD.
